

**Study Title**

**A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects with limited to no treatment options. TMC125-C216**

**Category**

Antiretroviral trial – Treatment Experienced

**Status**

Enrolment complete

**Primary Investigator at TGH**

Dr. Sharon Walmsley

**Sponsor**

Tibotec

**Brief Description of the Study**

A Phase II/III study comparing TMC125 + TMC114/RTV along with optimized background regimen vs. Optimized Background Regimen + TMC114/RTV alone in treatment experienced patients with  $\geq 3$  PI mutations. This is a placebo controlled double-blinded study with duration 48 weeks

**Contact**

Rosie Clarke – 416-340-4800 ext. 6723,  
email – [rosie.clarke@uhn.on.ca](mailto:rosie.clarke@uhn.on.ca)